Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,600
Employees17,600
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,600
Employees17,600

GILD Key Statistics

Market cap
188.15B
Market cap188.15B
Price-Earnings ratio
23.62
Price-Earnings ratio23.62
Dividend yield
2.07%
Dividend yield2.07%
Average volume
8.08M
Average volume8.08M
High today
$153.00
High today$153.00
Low today
$150.20
Low today$150.20
Open price
$152.42
Open price$152.42
Volume
7.43M
Volume7.43M
52 Week high
$153.13
52 Week high$153.13
52 Week low
$93.37
52 Week low$93.37

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $151.40, giving the company a market capitalization of 188.15B. It carries a P/E multiple of 23.62 and pays a dividend yield of 2.1%.

On 2026-02-10, Gilead Sciences(GILD) stock moved within a range of $150.20 to $153.00. With shares now at $151.40, the stock is trading +0.8% above its intraday low and -1.0% below the session's peak.

Trading volume for Gilead Sciences(GILD) stock has reached 7.43M, versus its average volume of 8.08M.

The stock's 52-week range extends from a low of $93.37 to a high of $153.13.

The stock's 52-week range extends from a low of $93.37 to a high of $153.13.

GILD News

Nasdaq 15h
Should You Buy Gilead Sciences Before Feb. 10?

Key Points Gilead Sciences' recent quarterly updates have been better than what the market expected. The company's results could improve with newer launches....

Should You Buy Gilead Sciences Before Feb. 10?
Simply Wall St 2d
Gilead Sciences Is Up 7.4% After FDA Expands Yescarta Lymphoma Label Restrictions Removed

In early February 2026, Kite, a Gilead company, reported that the FDA approved an update to Yescarta’s prescribing information, removing prior use limitations i...

Gilead Sciences Is Up 7.4% After FDA Expands Yescarta Lymphoma Label Restrictions Removed
TipRanks 4d
Kite announces FDA approval for updated Yescarta label

Kite, a Gilead (GILD) company, announced the FDA approved an update to the Yescarta prescribing information removing the previous Limitations of Use in patients...

Analyst ratings

74%

of 31 ratings
Buy
74.2%
Hold
22.6%
Sell
3.2%

More GILD News

Simply Wall St 4d
Gilead Sciences Valuation Check After Oncology And HIV Therapy Momentum

Gilead Sciences (GILD) has returned to focus after a series of company-specific catalysts, including its oncology expansion through Repare Therapeutics, FDA app...

Gilead Sciences Valuation Check After Oncology And HIV Therapy Momentum

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.